<SEC-DOCUMENT>0000950170-24-098103.txt : 20240816
<SEC-HEADER>0000950170-24-098103.hdr.sgml : 20240816
<ACCEPTANCE-DATETIME>20240816163536
ACCESSION NUMBER:		0000950170-24-098103
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240814
FILED AS OF DATE:		20240816
DATE AS OF CHANGE:		20240816

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Groenewald Ferdinand
		CENTRAL INDEX KEY:			0001734018
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33038
		FILM NUMBER:		241217184

	MAIL ADDRESS:	
		STREET 1:		C/O MUSCLE MAKER, INC,
		STREET 2:		2200 SPACE PARK DRIVE,SUITE 310
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77058

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2617 BISSONNET ST
		STREET 2:		SUITE 225
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77005
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		2617 BISSONNET ST
		STREET 2:		SUITE 225
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-08-14</periodOfReport>

    <issuer>
        <issuerCik>0001107421</issuerCik>
        <issuerName>Alaunos Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>TCRT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001734018</rptOwnerCik>
            <rptOwnerName>Groenewald Ferdinand</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ALAUNOS THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>2617 BISSONNET ST, SUITE 225</rptOwnerStreet2>
            <rptOwnerCity>HOUSTON</rptOwnerCity>
            <rptOwnerState>TX</rptOwnerState>
            <rptOwnerZipCode>770005</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>VP, Finance</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Employee Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>2.42</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2024-08-14</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>1500</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2034-08-13</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1500</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>1500</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">One-sixteenth of the shares underlying the option vest in equal quarterly installments measured from August 14, 2024, with the first vesting occurring on November 14, 2024 subject to the Reporting Person's continued service through each vesting date.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Melinda Lackey, Attorney-in-fact</signatureName>
        <signatureDate>2024-08-16</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
